Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00125970 · ClinicalTrials.gov registry record · Phase 2
HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 480
- Enrollment target
NCT00125970 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 480 participants.
The verdict
NCT00125970, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 480 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the safety of and immune response to a DNA HIV vaccine followed by an adenoviral vector HIV vaccine in HIV uninfected adults.
Interventions
- BIOLOGICAL VRC-HIVADV014-00-VP
- BIOLOGICAL VRC-HIVDNA016-00-VP
- BIOLOGICAL VRC-HIVDNA016-00-VP placebo
- BIOLOGICAL VRC-HIVADV014-00-VP placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2005-09 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00125970
The ClinicalTrials.gov registry entry for NCT00125970 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which VRC-HIVADV014-00-VP is the first listed.
NCT00125970 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00125970 about?
NCT00125970 is a clinical study titled "HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants". The purpose of the study is to determine the safety of and immune response to a DNA HIV vaccine followed by an adenoviral vector HIV vaccine in HIV uninfected adults.
What is the current status of trial NCT00125970?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 480 participants. The study started on 2005-09. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00125970?
The interventions under investigation include: VRC-HIVADV014-00-VP (BIOLOGICAL), VRC-HIVDNA016-00-VP (BIOLOGICAL), VRC-HIVDNA016-00-VP placebo (BIOLOGICAL), VRC-HIVADV014-00-VP placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT00125970?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.